Canbridge, UMass partner on gene therapies for neuromuscular diseases

By The Science Advisory Board staff writers

September 9, 2020 -- Canbridge Pharmaceuticals has expanded its gene-therapy partnership with the University of Massachusetts (UMass) Medical School.

Under the direction of Miguel Sena-Esteves, PhD, of UMass, the second sponsored program between Canbridge and the university will focus on the development of customized adeno-associated virus (AAV) vectors with broad applications for treating neuromuscular diseases, according to the company.

The new collaboration follows an agreement earlier this year to study gene therapy-based treatments with Guangping Gao, PhD, director of UMass Medical School's Horae Gene Therapy Center.


Copyright © 2020 scienceboard.net
 


Email Address:

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.